StockpollyBeta
Get App
Popularity #4,218
CRVO · NASDAQ · Biotechnology

CervoMed (CRVO)

Develops neflamapimod for age-related brain disorders.

$2.58
After hours+0.04 (+1.57%)
At close$2.54(+5.39%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Gross profit000000000000
323357578887
Research & development233457556654
222322232332
General & administrative222322232332
Other expenses−2−2−2−3−2−2−2−20000
Operating income−3−2−3−3−5−7−5−7−8−8−8−7
500111000000
Interest income000111000000
Other non-operating income0−60−1−1−1000000
Income before tax2−2−3−2−5−7−5−6−8−8−8−7
Net income from continuing operations2−2−3−2−5−7−5−6−8−8−8−7
Net income2−2−3−2−5−7−5−6−8−8−8−7
EPS, basic$0.65−$0.42−$0.41−$0.27−$0.55−$0.77−$0.56−$0.70−$0.84−$0.87−$0.86−$0.64
EPS, diluted−$0.70−$0.42−$0.41−$0.27−$0.55−$0.77−$0.56−$0.70−$0.84−$0.87−$0.86−$0.64
Weighted average shares, basic3669999999910
Weighted average shares, diluted4669999999910
EBITDA−33−3−2−5−7−5−6−8−8−8−7
EBIT−33−3−2−5−7−5−6−8−8−8−7